Clinical Trials

The primary aim of Part A of the study to assess the effectiveness and tolerability of GWP42003-P compared to placebo as an adjunctive treatment for children with Epilepsy with myoclonic-atonic seizures (EMAS) -associated seizures. Part B of this study will be conducted to evaluate the long-term safety and tolerability of GWP42003-P in participants with EMAS.

The purpose of this study is to evaluate the initial safety and effectiveness of Microburst VNS stimulation in subjects with refractory epilepsy.

The purpose of this study is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with idiopathic generalized epilepsy (IGE).

The objectives of this study are to assess the effectiveness of NBI-921352 as adjunctive therapy on the frequency of countable motor seizures (defined as generalized tonic-clonic seizure [GTCS], tonic, atonic or focal onset   seizures [FOS] with noticeable motor component), to evaluate the effectiveness of NBI-921352 using the Clinical and Parent/Caregiver Global Impression of Change scales and the Clinical and Parent/Caregiver Global Impression of Severity scales, to explore the effect of NBI-921352 on symptoms and seizure activity, physical activity, quality of life, as well as seizure freedom. to characterize the pharmacokinetics (PK) of NBI-921352 and determine the effect of NBI-921352 on plasma levels of concomitant antiseizure ...

The purpose of this study is to investigate if blood and/or MRI markers of inflammation and immune system activation may show changes in relation to when you have a seizure, and to noninvasively detect seizure related structural and functional alterations in acute seizure by MRI.